The role of automated insulin delivery technology in diabetes
Open accessThe DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
The role of automated insulin delivery systems in diabetes is expanding. Hybrid closed-loop systems are being used in routine clinical practice for treating people with type 1 diabetes. Encouragingly, real-world data reflects the performance and usability observed in clinical trials. We review the commercially available hybrid closed-loop systems, their distinctive features and the associated real-world data. We also consider emerging indications for closed-loop systems, including the treatment of type 2 diabetes where variability of day-to-day insulin requirements is high, and other challenging applications for this technology. We discuss issues around access and implementation of closed-loop technology, and consider the limitations of present closed-loop systems, as well as innovative approaches that are being evaluated to improve their performance. Graphical Abstract
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2 Variability of day-to-day insulin requirements as determined by closed-loop insulin delivery across different populations with diabetes. Data presented are mean with SD. Samples size: type 1 diabetes age 1–6 years n=20, 7–12 years n=21, 13–17 years n=18, adults n=58; type 2 diabetes outpatients n=25, inpatients n=67 (data from references [43, 44, 65]). IP, inpatients; OP, outpatients; T1D, type 1 diabetes, T2D, type 2 diabetes; y, years. This figure is available as part of a downloadable slideset](https://figures.cochat.ai/paper-figures/09c6de5336f046bfa7a7e934f56bade0/the-role-of-automated-insulin-delivery-technology-in-diabetes-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The greatest improvements were seen with AID when used in individuals with the highest baseline A1C or lowest TIR (220).”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [220]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
Brown, S. A., Kovatchev, B. P., Raghinaru, D., Lum, J. W., Buckingham, B. A., Kudva, Y. C., Laffel, L. M., Levy, C. J., Pinsker, J. E., Wadwa, R. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1907863 · Cited by 1,030 · cited 1×
“…Control-IQ hybrid closed-loop algorithm, hosted on the t:slim X2 insulin pump (Tandem, CA, USA), uses pre-programmed basal rates, correction factors and carbohydrate-to-insulin ratios as part of its algorithm inputs, while the correction target and active insulin time are fixed in the system [28].”
MethodFeig, D. S., Donovan, L. E., Corcoy, R., Murphy, K. E., Amiel, S. A., Hunt, K. F., Asztalos, E., Barrett, J. F. R., Sanchez, J. J., de Leiva, A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32400-5 · Cited by 803
Phillip, M., Nimri, R., Bergenstal, R. M., Barnard-Kelly, K., Danne, T., Hovorka, R., Kovatchev, B. P., Messer, L. H., Parkin, C. G., Ambler-Osborn, L., et al. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnac022 · Cited by 443
Self-citationBekiari, E., Kitsios, K., Thabit, H., Tauschmann, M., Athanasiadou, E., Karagiannis, T., Haidich, A.-B., Hovorka, R., & Tsapas, A. (2018) · BMJ · doi:10.1136/bmj.k1310 · Cited by 437
Self-citationMurphy, H. R., Howgate, C., O'Keefe, J., Myers, J., Morgan, M., Coleman, M. A., Jolly, M., Valabhji, J., Scott, E. M., Knighton, P., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30406-x · Cited by 346 · cited 1×
“Pregnant women with diabetes Attaining recommended tight glucose control during pregnancy is particularly difficult due to marked gestational variations in insulin sensitivity and altered eating patterns [45].”
BackgroundBergenstal, R. M., Nimri, R., Beck, R. W., Criego, A., Laffel, L., Schatz, D., Battelino, T., Danne, T., Weinzimer, S. A., Sibayan, J., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32514-9 · Cited by 344 · cited 1×
“…CA, USA) has been super-seded by the second generation MiniMed 780G, which has improved usability (fewer auto mode exits and alarms) and improved glucose management with automated bolus insulin corrections and a meal detection module in addition to the existing features of the MiniMed 670G [27].”
BackgroundOne Year Real-World Use of the Control-IQ Advanced Hybrid Closed-Loop Technology
Breton, M. D., & Kovatchev, B. P. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0097 · Cited by 250 · cited 1×
“Real-world usability has been reported in a smaller dataset (>9000 users) where time spent in closed-loop mode was 94% [36].”
BackgroundAutomated insulin delivery in women with pregnancy complicated by type 1 diabetes
Lee, T. T. M., Collett, C., Bergford, S., Hartnell, S., Scott, E. M., Lindsay, R. S., Hunt, K. F., McCance, D. R., Barnard-Kelly, K., Rankin, D., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2303911 · Cited by 241
Self-citationClosed-loop insulin delivery for glycemic control in noncritical care
Bally, L., Thabit, H., Hartnell, S., Andereggen, E., Ruan, Y., Wilinska, M. E., Evans, M. L., Wertli, M. M., Coll, A. P., Stettler, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805233 · Cited by 232 · cited 1×
“The same fully automated closed-loop system has also shown safety and efficacy in inpatients during acute hospital admissions [14, 15].”
BackgroundSelf-citationBenhamou, P.-Y., Franc, S., Reznik, Y., Thivolet, C., Schaepelynck, P., Renard, E., Guerci, B., Chaillous, L., Lukas-Croisier, C., Jeandidier, N., et al. (2019) · The Lancet Digital Health · doi:10.1016/s2589-7500(19)30003-2 · Cited by 217 · cited 1×
“DBLG1 allows users to customise the algorithm through ten different settings including target glucose level and hypoglycaemia threshold [29].”
BackgroundMulticenter, randomized trial of a bionic pancreas in type 1 diabetes
Bionic Pancreas Research Group (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2205225 · Cited by 216
One year clinical experience of the first commercial hybrid closed-loop system
Lal, R. A., Basina, M., Maahs, D. M., Hood, K., Buckingham, B., & Wilson, D. M. (2019) · Diabetes Care · doi:10.2337/dc19-0855 · Cited by 215 · cited 1×
“Usability, reflected by a sustained high time spent in closed-loop mode (>95%), is critical to realising the clinical benefits of closed-loop systems [53].”
BackgroundArrieta, A., Battelino, T., Scaramuzza, A. E., Da Silva, J., Castañeda, J., Cordero, T. L., Shin, J., & Cohen, O. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14714 · Cited by 154
Lum, J. W., Bailey, R. J., Barnes-Lomen, V., Naranjo, D., Hood, K. K., Lal, R. A., Arbiter, B., Brown, A. S., DeSalvo, D. J., Pettus, J., et al. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0535 · Cited by 150 · cited 1×
“Time in target glucose range was 73% and time with glucose 3.9 mmol/l was 2.8% [40].”
BackgroundInfluentialBraune, K., Lal, R. A., Petruželková, L., Scheiner, G., Winterdijk, P., Schmidt, S., Raimond, L., Hood, K. K., Riddell, M. C., Skinner, T. C., et al. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00267-9 · Cited by 130
Boughton, C. K., Tripyla, A., Hartnell, S., Daly, A., Herzig, D., Wilinska, M. E., Czerlau, C., Fry, A., Bally, L., & Hovorka, R. (2021) · Nature Medicine · doi:10.1038/s41591-021-01453-z · Cited by 125 · cited 1×
“…an increase in hypoglycaemia, compared with standard insulin therapy, in adults with type 2 diabetes and sub-optimal glucose management at baseline using a fully automated closed-loop system (CamAPS HX, CamDiab, UK), which does not require any meal announcement, in an outpatient setting [12, 13].”
BackgroundSelf-citationHermann, J. M., Miller, K. M., Hofer, S. E., Clements, M. A., Karges, W., Foster, N. C., Fröhlich‐Reiterer, E., Rickels, M. R., Rosenbauer, J., DeSalvo, D. J., et al. (2020) · Diabetic Medicine · doi:10.1111/dme.14148 · Cited by 120
Daly, A. B., Boughton, C. K., Nwokolo, M., Hartnell, S., Wilinska, M. E., Cezar, A., Evans, M. L., & Hovorka, R. (2023) · Nature Medicine · doi:10.1038/s41591-022-02144-z · Cited by 120
Self-citationBeck, R. W., Kanapka, L. G., Breton, M. D., Brown, S. A., Wadwa, R. P., Buckingham, B. A., Kollman, C., & Kovatchev, B. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0558 · Cited by 111
Boughton, C. K., Bally, L., Martignoni, F., Hartnell, S., Herzig, D., Vogt, A., Wertli, M. M., Wilinska, M. E., Evans, M. L., Coll, A. P., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30061-0 · Cited by 110 · cited 1×
“The same fully automated closed-loop system has also shown safety and efficacy in inpatients during acute hospital admissions [14, 15].”
BackgroundSelf-citationPredictors of time in target glucose range in real‐world users of the MiniMed 780G system
Castañeda, J., Mathieu, C., Aanstoot, H., Arrieta, A., Da Silva, J., Shin, J., & Cohen, O. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14807 · Cited by 106
Forlenza, G. P., DeSalvo, D. J., Aleppo, G., Wilmot, E. G., Berget, C., Huyett, L. M., Hadjiyianni, I., Méndez, J. J., Conroy, L. R., Ly, T. T., et al. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0578 · Cited by 99
Dovc, K., Boughton, C., Tauschmann, M., Thabit, H., Bally, L., Allen, J. M., Acerini, C. L., Arnolds, S., de Beaufort, C., Bergenstal, R. M., et al. (2019) · Diabetes Care · doi:10.2337/dc18-2625 · Cited by 97 · cited 2×
“The greatest variability in day-to-day insulin requirements in those with type 1 diabetes is in very young children [44] (Fig.”
BackgroundSelf-citationBoughton, C. K., Hartnell, S., Thabit, H., Poettler, T., Herzig, D., Wilinska, M. E., Ashcroft, N. L., Sibayan, J., Cohen, N., Calhoun, P., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14355 · Cited by 96
Self-citationSpeight, J., Choudhary, P., Wilmot, E. G., Hendrieckx, C., Forde, H., Cheung, W. Y., Crabtree, T., Millar, B., Traviss‐Turner, G., Hill, A., et al. (2023) · Diabetic Medicine · doi:10.1111/dme.14944 · Cited by 92
Karageorgiou, V., Papaioannou, T. G., Bellos, I., Alexandraki, K., Tentolouris, N., Stefanadis, C., Chrousos, G. P., & Tousoulis, D. (2019) · Metabolism · doi:10.1016/j.metabol.2018.10.002 · Cited by 89
Choudhary, P., Arrieta, A., van den Heuvel, T. R. A., Castañeda, J., Smaniotto, V., & Cohen, O. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0433 · Cited by 89 · cited 1×
“Data from over 100,000 Medtronic 780G users across Europe, the Middle East and Africa showed that time spent in closed-loop mode was 90%, while time spent in target glucose range (3.9 to 10.0 mmol/l) was 72.3% with 2.0% of time spent below target range [33].”
BackgroundInfluentialCrabtree, T. S. J., Griffin, T. P., Yap, Y. W., Narendran, P., Gallen, G., Furlong, N., Cranston, I., Chakera, A., Philbey, C., Karamat, M. A., et al. (2023) · Diabetes Care · doi:10.2337/dc23-0635 · Cited by 88
Blauw, H., Onvlee, A. J., Klaassen, M., van Bon, A. C., & DeVries, J. H. (2021) · Diabetes Care · doi:10.2337/dc20-2106 · Cited by 84 · cited 1×
“Dual hormone closed-loop systems using insulin and pram-lintide or insulin and glucagon have been evaluated in clinical trials but add complexity and cost, and are associated with gastrointestinal side effects [59, 60].”
BackgroundAkturk, H. K., Agarwal, S., Hoffecker, L., & Shah, V. N. (2021) · Diabetes Care · doi:10.2337/dc20-3063 · Cited by 81 · cited 1×
“Training and support resources It is important to note that reports of user experiences from closed-loop studies are limited by the relative lack of ethnic and socioeconomic diversity of the research study populations [26].”
BackgroundJiao, X., Shen, Y., & Chen, Y. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002633 · Cited by 76
Davis, G. M., Peters, A. L., Bode, B. W., Carlson, A. L., Dumais, B., Vienneau, T. E., Huyett, L. M., & Ly, T. T. (2023) · Diabetes Care · doi:10.2337/dc22-1915 · Cited by 69
Godoi, A., Reis Marques, I., Padrão, E. M. H., Mahesh, A., Hespanhol, L. C., Riceto Loyola Júnior, J. E., de Souza, I. A. F., Moreira, V. C. S., Silva, C. H., Miyawaki, I. A., et al. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01144-4 · Cited by 67
Cobry, E. C., Bisio, A., Wadwa, R. P., & Breton, M. D. (2022) · Diabetes Care · doi:10.2337/dc21-1778 · Cited by 64
Rankin, D., Kimbell, B., Hovorka, R., & Lawton, J. (2021) · Chronic Illness · doi:10.1177/1742395320985924 · Cited by 62
Self-citationBoughton, C. K., Hartnell, S., Lakshman, R., Nwokolo, M., Wilinska, M. E., Ware, J., Allen, J. M., Evans, M. L., & Hovorka, R. (2023) · Diabetes Care · doi:10.2337/dc23-0728 · Cited by 60
Self-citationReal-world evidence of automated insulin delivery system use
Considine, E. G., & Sherr, J. L. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0442 · Cited by 59
Tsoukas, M. A., Majdpour, D., Yale, J.-F., Fathi, A. E., Garfield, N., Rutkowski, J., Rene, J., Legault, L., & Haidar, A. (2021) · The Lancet Digital Health · doi:10.1016/s2589-7500(21)00139-4 · Cited by 58 · cited 1×
“Dual hormone closed-loop systems using insulin and pram-lintide or insulin and glucagon have been evaluated in clinical trials but add complexity and cost, and are associated with gastrointestinal side effects [59, 60].”
BackgroundNg, S. M., Wright, N. P., Yardley, D., Campbell, F., Randell, T., Trevelyan, N., Ghatak, A., & Hindmarsh, P. C. (2023) · Diabetic Medicine · doi:10.1111/dme.15015 · Cited by 57 · cited 1×
“An NHS England pilot study evaluating real-world implementation of hybrid closed-loop technology included 251 children and 570 adults with type 1 diabetes [41, 42].”
BackgroundListening to Women: Experiences of Using Closed-Loop in Type 1 Diabetes Pregnancy
Lawton, J., Kimbell, B., Closs, M., Hartnell, S., Lee, T., Dover, A. R., Reynolds, R. M., Collett, C., Barnard-Kelly, K. D., Hovorka, R., et al. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0323 · Cited by 56
Self-citationLawton, J., Kimbell, B., Rankin, D., Ashcroft, N. L., Varghese, L., Allen, J. M., Boughton, C. K., Campbell, F., Randell, T., Besser, R. E. J., et al. (2020) · Diabetic Medicine · doi:10.1111/dme.14252 · Cited by 54 · cited 1×
“Healthcare professional workload, as well as bias as to who might use the closed-loop system most effectively and derive most benefit from it, are important contributors to inequalities in access to this technology for people with diabetes [52].”
BackgroundSelf-citationRenard, E., Joubert, M., Villard, O., Dreves, B., Reznik, Y., Farret, A., Place, J., Breton, M. D., Kovatchev, B. P., & iDCL Trial Research Group (2023) · Diabetes Care · doi:10.2337/dc23-0685 · Cited by 51
Janež, A., Battelino, T., Klupa, T., Kocsis, G., Kuricova, M., Lalic, N. M., Stoian, A. P., Prázný, M., Rahelić, D., Šoupal, J., et al. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01160-5 · Cited by 48
Ekhlaspour, L., Town, M., Raghinaru, D., Lum, J. W., Brown, S. A., Buckingham, B. A., & for the iDCL Trial Research Group (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0524 · Cited by 48
Real-World Evidence Analysis of a Hybrid Closed-Loop System
Alwan, H., Wilinska, M. E., Ruan, Y., Silva, J. D., & Hovorka, R. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231185348 · Cited by 43
Self-citationHaidar, A., Yale, J., Lovblom, L. E., Cardinez, N., Orszag, A., Falappa, C. M., Gouchie‐Provencher, N., Tsoukas, M. A., El Fathi, A., Rene, J., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14335 · Cited by 42 · cited 1×
“…management, such as glucagon-like peptide-1 (GLP-1) receptor agonists and sodium–glucose cotransporter 2 (SGLT-2) inhibitors may allow for a fully closed-loop sys-tem, with small studies showing feasibility; however there are concerns around an increased risk of diabetic ketoacidosis [61, 62].”
BackgroundIlkowitz, J. T., Katikaneni, R., Cantwell, M., Ramchandani, N., & Heptulla, R. A. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816647976 · Cited by 39
Kimbell, B., Rankin, D., Hart, R. I., Allen, J. M., Boughton, C. K., Campbell, F., Fröhlich-Reiterer, E. E., Hofer, S. E., Kapellen, T. M., Rami-Merhar, B. M., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109877 · Cited by 39
Self-citationFlatt, A. J., Peleckis, A. J., Dalton-Bakes, C., Nguyen, H.-L., Ilany, S., Matus, A., Malone, S. K., Goel, N., Jang, S., Weimer, J., et al. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0506 · Cited by 39
Özer, K., Cooper, A. M., Ahn, L. P., Waggonner, C. R., & Blevins, T. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0500 · Cited by 38 · cited 1×
“Ultra-rapid insulins have the potential to improve closed-loop performance [54–57]; however, while the use of ultra-rapid Lispro in a fully closed-loop system reduced burden, this was at the expense of optimal glucose management [58].”
BackgroundLee, M. H., Paldus, B., Vogrin, S., Morrison, D., Zaharieva, D. P., Lu, J., Jones, H. M., Netzer, E., Robinson, L., Grosman, B., et al. (2021) · Diabetes Care · doi:10.2337/dc21-0814 · Cited by 37
Jacobs, P. G., Resalat, N., Hilts, W., Young, G. M., Leitschuh, J., Pinsonault, J., El Youssef, J., Branigan, D., Gabo, V., Eom, J., et al. (2023) · The Lancet Digital Health · doi:10.1016/s2589-7500(23)00112-7 · Cited by 37
Levy, C. J., Raghinaru, D., Kudva, Y. C., Pandit, K., Blevins, T., Casaubon, L., Desjardins, D., Levister, C. M., O’Malley, G., Reid, C., et al. (2024) · Clinical Diabetes · doi:10.2337/cd23-0025 · Cited by 37
Messer, L. H., & Breton, M. D. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0308 · Cited by 37
Benhamou, P., Adenis, A., Lebbad, H., Tourki, Y., Heredia, M., Gehr, B., Franc, S., & Charpentier, G. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15008 · Cited by 35
Nwokolo, M., Lakshman, R., Hartnell, S., Alwan, H., Ware, J., Allen, J. M., Wilinska, M. E., Evans, M. L., Hovorka, R., & Boughton, C. K. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0262 · Cited by 34
Self-citationSmartwatch gesture‐based meal reminders improve glycaemic control
Corbett, J. P., Hsu, L. J., Brown, S. A., Kollar, L. L., Vleugels, K., Buckingham, B. A., Breton, M. D., & Lal, R. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14737 · Cited by 32 · cited 1×
“Innovative approaches to improving performance of closed-loop systems include incorporation of signals from other wearables such as a smartwatch app that detects eating behaviour [63] or a fitness sensor for detecting exercise/ activity [64].”
BackgroundGianini, A., Suklan, J., Skela‐Savič, B., Klemenčič, S., Battelino, T., Dovč, K., & Bratina, N. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.967725 · Cited by 27
Sherwood, J. S., Castellanos, L. E., O’Connor, M. Y., BALLIRO, C. A., HILLARD, M. A., Gaston, S. G., Bartholomew, R. A., Greaux, E. G., Sabean, A., Zheng, H., et al. (2023) · Diabetes Care · doi:10.2337/dc23-1411 · Cited by 24
Boughton, C. K., DALY, A. B., Thabit, H., Hartnell, S., Herzig, D., Vogt, A. P., Ruan, Y., Wilinska, M. E., Evans, M. L., Coll, A. P., et al. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14396 · Cited by 17
Self-citationBolusing frequency and amount impacts glucose control during hybrid closed‐loop
Bally, L., Thabit, H., Ruan, Y., Mader, J. K., Kojzar, H., Dellweg, S., Benesch, C., Hartnell, S., Leelarathna, L., Wilinska, M. E., et al. (2017) · Diabetic Medicine · doi:10.1111/dme.13436 · Cited by 11 · cited 1×
“Optimal performance with hybrid closed-loop systems is associated with increased bolus frequency and a higher proportion of total daily insulin delivered as a bolus [10, 11].”
BackgroundSelf-citationLakshman, R., DALY, A. B., Nwokolo, M., Hartnell, S., Wilinska, M. E., Cezar, A., Evans, M. L., Hovorka, R., & Boughton, C. K. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0073 · Cited by 7
Self-citation
Research works printed but not linked: 2
- International Diabetes Federation (2019) IDF Diabetes Atlas 9th Edition 2019. Available from https://diabetesatlas.org/idfawp/resource-files/2019/07/IDF_diabetes_atlas_ninth_edition_en.pdf
- National Institute for Health and Care Excellence (2023) Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes. Technology appraisal guidance. TA943. Available from https://www.nice.org.uk/guidance/ta943, published 19 Dec 2023 40245209
Cited by
7. Diabetes Technology: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s007 · Cited by 348
7. Diabetes Technology: Standards of Care in Diabetes—2026
Bajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., ChallaSivaKanaka, S., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s007 · Cited by 280
Wang, X., Si, J., Li, Y., Tse, P., Zhang, G., Wang, X., Ren, J., Xu, J., Sun, J., & Yao, X. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01819-0 · Cited by 33
“This intelligent regulation helps mitigate the risks of hyperglycemia and hypoglycemia, thereby improving overall glycemic management [29, 31, 37–39].”
Towards Personalized AI-Based Diabetes Therapy: A Review
Campanella, S., Paragliola, G., Cherubini, V., Pierleoni, P., & Palma, L. (2024) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2024.3443137 · Cited by 38
“Nowadays, a person with diabetes can also receive decision support from a medical professional who makes recommendations via a mobile interface, or directly from the patient using a smartphone app that generates recommendations on its own [8], [9], [10].”
BackgroundDe Meulemeester, J., Keymeulen, B., De Block, C., Van Huffel, L., Taes, Y., Ballaux, D., Spincemaille, K., Lapauw, B., Vanhaverbeke, G., Lowyck, I., et al. (2025) · Diabetologia · doi:10.1007/s00125-025-06366-x · Cited by 27
“The superiority of HCL systems compared with other intensive insulin regimens in improving glucose management, minimising hypoglycaemia and enhancing quality of life for people with type 1 diabetes from all ages has been established in numerous RCTs [1–12].”
Metadata
- Authors
- Boughton, C. K., & Hovorka, R.
- Affiliations
- University of Cambridge (GB)
- Corresponding author
- Boughton, Charlotte K.
- Venue
- Diabetologia
- Published
- 2024-05-13
- Volume
- 67
- Issue
- 10
- Pages
- 2034-2044
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- PMC
- PMC11457686
- OpenAlex
- W4396850881
- Cited by
- 57
- References
- 62
- Citations by year
- 2026: 26 · 2025: 25 · 2024: 6
- FWCI
- 3.35
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Diabetologia (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Apollo (University of Cambridge) (submittedVersion, cc-by)
- Apollo (cc-by)
- Funders
- National Institute for Health and Care Research (14/23/09)
- Department of Health and Social Care
- NIHR Cambridge Biomedical Research Centre
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- artificial pancreas, hybrid closed-loop system, type 1 diabetes, type 2 diabetes, insulin pump therapy, real-world data
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Insulin, Insulin Infusion Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.